Scott Tagawa, MD, MS, detailed 2 presentations from ESMO’s presidential symposium that he thinks will have an impact on treating patients with metastatic castration-sensitive prostate cancer.
Scott T. Tagawa, MD, MS, a professor of medicine at Weill Cornell Medicine and physician at NewYork-Presbyterian – Weill Cornell Medical Center, spoke with CancerNetwork® following the 2021 European Society for Medical Oncology (ESMO) Congress about a pair of presentations from the presidential symposium that detailed the long-term benefits of intensified systemic therapy for patients with prostate cancer.
The first was the PEACE-1 trial (NCT01957436), which found that patients with metastatic castration-sensitive prostate cancer experienced improved radiographic progression-free survival and overall survival with the addition of prednisone and abiraterone acetate (Zytiga) to androgen-deprivation therapy (ADT) plus docetaxel.1
The other study was the STAMPEDE trial (NCT00268476), where the addition of abiraterone acetate and prednisolone with or without enzalutamide (Xtandi) to ADT improved survival outcomes for patients with high-risk nonmetastatic prostate cancer.2
There were 2 presidential symposium presentations at [ESMO], that both had to do with non-castrate disease, or early non-castrate disease in the high-risk or locally advanced setting…what some people call metastatic hormone-sensitive or castration-sensitive. If I were to put them together, they said the same thing [and that is] that intensified systemic therapy leads to downstream long-term improvements in overall survival. I think that we need to get that message out and see what’s out there.